Donor T-cell therapy for CD19-positive leukemia in young patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new treatment using donor immune cells (T-cells) that target a protein called CD19 on leukemia cells. It is for children and young adults with CD19-positive leukemia that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger.
- You must have CD19-positive leukemia that has returned or not responded to standard treatment.
- You must have tried at least two standard treatments (like chemotherapy).
- Your heart, kidneys, lungs, and liver must be working adequately.
- You must not have severe, uncontrolled infections or HIV.
- If you are a female who can have children, you must not be pregnant or breastfeeding and must agree to use birth control.
- You must not be receiving certain treatments (like systemic steroids) shortly before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially trained to find and kill cancer cells that have a protein called CD19 on them. It is for patients whose leukemia or lymphoma has come back or not gone away after standard treatments.
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Hear when a new Acute Lymphoblastic Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.